Sienna secures first deal for SCD-A7

Melbourne’s Sienna Cancer Diagnostics has won its first sales deal in the US, signing an agreement to provide its lead antibody product to uropathology lab Bostwick Laboratories.

Sienna will supply its Anti-hTERT antibody SCD-A7 to the laboratory for bladder cancer screening.

This is also the company’s first revenue-generating application of Sienna’s proprietary telomerase detection technology based on the SCD-A7 antibody.

Bostwick Laboratories will in turn become the first uropathology service provider in the world to offer a telomerase-based diagnostic stain for bladder cancer. The company will include Sienna’s reagent in its CytologyPro XT test.

“Today marks a huge milestone for Sienna,” managing director Dr Kerry Herarty said. “Bostwick Laboratories processes an extraordinary number of urine samples each year and is an ideal first partner for the use of SCD-A7 in bladder cancer.”

He said the company is working to expand the geographic presence for SCD-A7 while rolling out the stain platform to applications beyond bladder cancer.

Bladder cancer is the fifth most common cancer in the US, with more than 74,500 cases diagnosed last year.

Sienna registered SCD-A7 with the US FDA in March. The company also recently closed a $2.1 million placement and options exercise to help fund its SCD-A7 and other development efforts.

Image credit: ©freeimages.com/profile/Yello-Dog